NCT05089084Phase 3Completed

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-04-29Actual
Enrollment · participants75Actual
Source updated2026-06-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10. After: Measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview